Abstract
To quantify work productivity among patients with axial spondyloarthritis (axSpA) treated with biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have